Survey to Specify SGLT2 Inhibitor Choice in T2DM Management

Abstract

Objective: There are no major head-to-head comparative studies till date to compare the differences in glycemic efficacy, safety, or cardio-renal effects within SGLT2 inhibitors. This survey was conducted to understand the different parameters that clinicians identify while choosing an SGLT2 inhibitor in routine clinical practice. Materials and methods: A cross-sectional questionnaire-based survey of healthcare professionals (HCP) was conducted across India. Data were analyzed and expressed as descriptive statistics. Results: In clinical practice, the majority of HCPs identified a history of cardiovascular disease (CVD) as the most important factor for prescribing SGLT2 inhibitors in patients with T2DM. The majority of HCPs opined that among all the SGLT2 inhibitors, canagliflozin had the strongest effect on HbA1c reduction (56%), reduction in body weight (59%), and renal benefit (66%), whereas empagliflozin was associated with CV benefits (48%). In terms of heart failure, canagliflozin, empagliflozin, and dapagliflozin were similarly preferred. Conclusions: This survey gives us an understanding of the current clinical practice prevalent among Indian physicians as far as the prescription pattern of SGLT2 inhibitors is concerned.